30-day average of 13 articles ยท scale โ100 to +100
Across 13 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Cencora news is Bullish (+60)
on a scale from โ100 to +100.
That is up 19 points from the previous 30 days (+41).
Cencora stock sets specialty-led path for fiscal 2027
AI-generated analysis
Key insights
๐ Cencora reported fiscal fourth-quarter revenue of $88.4 billion, a 5.5% increase from the prior-year quarter.
๐ฐ Adjusted diluted earnings per share surged 21.4% year-over-year to $4.66, driven by higher gross profit and the OneOncology acquisition.
๐ The company reorganized its fiscal 2027 structure to center on specialty services, which are expected to grow revenue at 9% to 14%.
๐ต Cencora raised its quarterly dividend by 10% to $0.66 per share, payable on November 30.
๐ Management forecasts fiscal 2027 adjusted diluted EPS between $19.40 and $19.75, implying 8% to 10% growth.
๐ค The company plans to acquire American Oncology Network and sell its stake in Profarma to optimize the portfolio.
๐ Bullish signals
๐ฐCencora reported a significant 21.4% year-over-year increase in adjusted diluted earnings per share to $4.66, driven by higher gross profit and the OneOncology acquisition.
๐ตThe company raised its quarterly dividend by 10% to $0.66 per share, signaling confidence in cash flow generation and shareholder returns.
๐Management expects the specialty division to be the primary growth engine for fiscal 2027, with revenue projected to grow between 9% and 14%.
๐Cencora reaffirmed its long-term target of 10% to 14% adjusted diluted EPS growth, maintaining a strong trajectory for shareholder value.
๐ฐThe acquisition of OneOncology contributed directly to improved operating performance and supported the transition toward higher-margin specialty services.
Article
Cencora Inc. reported strong fiscal fourth-quarter results on November 4, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% year-over-year to $4.66. The company also posted GAAP EPS of $2.71, a significant turnaround from a loss in the prior period, driven by higher gross profit and the acquisition of OneOncology.
Management has reorganized its reporting structure for fiscal 2027 to prioritize specialty services, which are projected to outpace traditional distribution growth. The specialty division is expected to grow revenue between 9% and 14%, compared to 4% to 6% for the pharmaceutical distribution segment, reflecting a strategic shift toward higher-growth areas.
For fiscal 2027, Cencora forecasts adjusted diluted earnings per share between $19.40 and $19.75, representing 8% to 10% growth from the prior year. The company also raised its quarterly dividend by 10% to $0.66 per share and plans further portfolio moves, including the acquisition of American Oncology Network and the sale of its stake in Profarma.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Strs Ohio reduced its stake in Cencora, Inc. (NYSE:COR) by 4.7% during the first quarter, selling 2,506 shares to hold a remaining position of 51,180 shares valued at $16.078 million according to recent SEC filings. While Strs Ohio exited a portion of its holdings, several other institutional investors and hedge funds established or increased positions in the fourth quarter, including Kemnay Advisory Services, Oakworth Capital, Elyxium Wealth, Motiv8 Investments, and Archer Investment Corp, which significantly boosted its stake by 134.3%.
Cencora reported first-quarter earnings of $4.75 per share, missing analyst consensus estimates of $4.82 by seven cents, while revenue reached $78.36 billion against an estimate of $81.09 billion. The company achieved a year-over-year revenue increase of 3.9% and maintains a market capitalization of $57.67 billion with a debt-to-equity ratio of 3.40. Analysts currently predict full-year 2026 earnings of $17.79, slightly above the company's guidance range of $17.65 to $17.90.
The company announced a new stock buyback plan approved by its Board of Directors on May 21st, authorizing the repurchase of up to $2.00 billion in shares, which represents approximately 3.9% of its outstanding equity. Additionally, Cencora paid a quarterly dividend of $0.60 per share on June 1st, resulting in an annualized yield of 0.8% and a dividend payout ratio of 18.40%. Director Lauren M. Tyler also purchased 550 shares for approximately $148,626, increasing her direct ownership by 14.44%.
๐ Strs Ohio sold 2,506 shares, reducing stake to $16.078 million.
๐ Archer Investment Corp increased holdings by 134.3% in Q4.
๐ฐ Q1 revenue hit $78.36 billion despite missing EPS estimates.
๐ Board approved $2.0 billion buyback plan for up to 3.9% of shares.
๐ต Quarterly dividend of $0.60 sets annualized yield at 0.8%.
๐ Strs Ohio lowered its stake in Cencora by 4.7% in Q1, selling 2,506 shares while retaining a position worth $16.078 million.
๐ Multiple hedge funds and institutional investors initiated or increased positions in Q4, with Archer Investment Corp boosting its holding by 134.3%.
๐ฐ Cencora reported Q1 revenue of $78.36 billion, representing a 3.9% year-over-year increase despite missing EPS estimates by $0.07.
๐ The Board approved a new $2.00 billion stock buyback plan authorized to repurchase up to 3.9% of outstanding shares.
๐ต The company paid a quarterly dividend of $0.60 per share on June 1st, establishing an annualized yield of 0.8%.
๐ Director Lauren M. Tyler purchased 550 shares for $148,626.50, increasing her personal stake by 14.44% to 4,359 shares.
๐ Cencora holds a market cap of $57.67 billion with a P/E ratio of 22.73 and a beta of 0.58.
๐ฏ Analysts forecast full-year 2026 EPS of $17.79, which is slightly higher than the company's guidance range of $17.65-$17.90.
Bullish Signals
$2.00 billion buyback plan approved.
Revenue up 3.9% to $78.36 billion.
Institutional stake rose 134.3% in Q4.
Dividend yield of 0.8% with 18.40% payout.
Director ownership increased by 14.44%.
Risk Factors
EPS missed estimates by $0.07 at $4.75 vs $4.82.
Revenue fell short at $78.36B vs $81.09B expectations.
Strs Ohio reduced holdings by 4.7% in Q1.
Bullish Signals
Cencora announced a substantial $2.00 billion stock buyback plan approved by the Board of Directors, signaling management confidence in the stock's valuation.
The company reported a 3.9% year-over-year revenue increase to $78.36 billion, demonstrating continued growth in its pharmaceutical distribution business.
Archer Investment Corp significantly increased its stake by 134.3% in Q4, indicating strong institutional interest from major investors.
Cencora maintains a healthy dividend yield of 0.8% with a low payout ratio of 18.40%, providing consistent income to shareholders.
Director Lauren M. Tyler increased her personal ownership by 14.44% through a significant purchase, aligning insider interests with shareholders.
Risk Factors
Cencora missed first-quarter earnings per share estimates by $0.07, reporting $4.75 against the consensus of $4.82.
The company reported revenue of $78.36 billion, which fell short of analyst expectations of $81.09 billion for the quarter.
Strs Ohio reduced its holdings by 4.7% in Q1, indicating a lack of confidence or a need to rebalance from this specific institutional investor.
TimesSquare Capital Management highlighted Cencora (COR) in its fourth-quarter 2025 investor letter, noting an 8% share price gain. The firm cited fiscal Q4 earnings that outpaced consensus estimates, driven by strength in the U.S. market which offset a miss in international business. This positive performance contributed to the stock's broader 24.05% gain over the past 52 weeks.
The investment strategy favors healthcare companies providing novel therapies or specialized services. Regarding Cencora specifically, management announced it is considering strategic alternatives for its animal health and non-core PharmaLex business segments. Despite this, hedge fund portfolios holding Cencora increased to 61 from 59 at the end of the quarter.
In the first quarter of fiscal 2026, Cencora's consolidated revenue rose 5.5% year-over-year to $85.9 billion due to solid growth across both reportable segments. The company has a market capitalization of approximately $64.5 billion. While TimesSquare Capital maintains conviction in certain AI stocks for higher returns, it acknowledges the risk and potential inherent in Cencora as an investment.
๐ COR shares rose 8% after Q4 earnings beat estimates.
๐บ๐ธ Strong U.S. business offset international operations miss.
๐ผ Management exploring strategic alternatives for non-core segments.
๐ Hedge fund holdings increased to 61 by end of Q4 2025.
๐ฐ Consolidated revenue grew 5.5% YoY in fiscal Q1 2026.
๐ Cencora (COR) shares rose 8% following fiscal fourth-quarter earnings that beat consensus estimates.
๐บ๐ธ U.S. business strength offset a miss in international operations during the reported quarter.
๐ผ Management is considering strategic alternatives for animal health and non-core PharmaLex segments.
๐ Hedge fund portfolios holding Cencora increased to 61 at the end of Q4 2025.
๐ฐ Consolidated revenue grew 5.5% year-over-year in fiscal Q1 2026 to reach $85.9 billion.
๐ One-month return for Cencora was -8.13% as of March 19, 2026.
๐ข The company holds a market capitalization of approximately $64.5 billion.
๐ง TimesSquare Capital prefers AI stocks over Cencora for delivering higher returns in shorter timeframes.
Bullish Signals
Q4 earnings beat consensus estimates.
U.S. segments offset international miss.
Fiscal 2026 Q1 revenue up 5.5% to $85.9B.
Hedge fund portfolios rose from 59 to 61.
Risk Factors
Q4 international business missed consensus estimates.
Considering strategic alternatives for animal health and PharmaLex.
Analyst prefers AI stocks over Cencora for returns.
U.S. business segments provided strength that successfully offset a miss in international operations.
Consolidated revenue increased 5.5% year-over-year in the first quarter of fiscal 2026 to $85.9 billion.
Hedge fund interest grew with portfolios holding Cencora rising from 59 to 61 at the end of Q4 2025.
Risk Factors
Cencora's international business missed consensus estimates during the fiscal fourth quarter.
The company is considering strategic alternatives for its animal health and non-core PharmaLex segments, indicating potential restructuring or divestiture activity.
TimesSquare Capital expressed a preference for AI stocks over Cencora regarding higher return potential.
Cencora, Inc. (NYSE: COR) announced a strategic acquisition of EyeSouth's partner's retina business for $1.1 billion, marking a significant expansion into the specialty pharmaceutical services sector. The deal is financed through existing credit facilities and cash reserves, with analysts from UBS and Evercore ISI reiterating their Buy/Outperform ratings and raising price targets to $410 and $420 respectively.
The acquisition is expected to be accretive to adjusted earnings per share within the first 12 months following the transaction's close. This move strengthens Cencora's existing retina platform, which generated $600 million in revenue and $75 million in EBITDA in 2022, while creating synergies with its current RCA business by integrating all providers onto a unified platform.
Cencora operates as a leading global pharmaceutical solutions organization, acting as a primary wholesale distributor connecting drug manufacturers with healthcare providers. The company distributes brand-name, generic, and specialty drugs to hospitals, pharmacies, and clinics while providing logistics, supply chain optimization, and commercialization services for biopharma companies.
๐ Cencora acquires EyeSouth's retina business for $1.1 billion.
๐ฐ Deal funded via existing credit facilities and cash reserves.
๐ Analysts maintain Buy ratings with price targets of $410-$420.
๐ Projected to be accretive to EPS within 12 months.
๐ผ Retina platform generated $600M revenue and $75M EBITDA in 2022.
๐ Cencora (COR) acquires EyeSouth's partner's retina business for a total deal value of $1.1 billion.
๐ฐ The acquisition is financed using the company's existing credit facilities and available cash reserves.
๐ Analysts UBS and Evercore ISI maintain Buy/Outperform ratings with price targets of $410 and $420.
๐ The deal is projected to be accretive to adjusted earnings per share within the first 12 months post-close.
๐ผ The transaction strengthens Cencora's retina platform, which generated $600M revenue and $75M EBITDA in 2022.
๐ค The acquisition creates synergies with the existing RCA business by integrating all providers onto a single platform.
๐ฅ Cencora operates as a primary wholesale distributor connecting drug manufacturers with hospitals, pharmacies, and clinics.
Bullish Signals
$1.1B acquisition accretive to EPS within 12 months.
UBS and Evercore ISI rate Buy with $410-$420 targets.
Expands into high-growth specialty segment diversifying revenue.
Existing retina platform generated $600M revenue and $75M EBITDA in 2022.
Unified platform integration expected to generate significant cost synergies.
Bullish Signals
The $1.1 billion acquisition of EyeSouth's retina business is expected to be accretive to adjusted earnings per share within the first 12 months following the close.
Major investment banks UBS and Evercore ISI have reiterated Buy/Outperform ratings with price targets of $410 and $420, signaling strong institutional confidence in the deal's value creation.
The acquisition expands Cencora into a high-growth specialty business segment, diversifying its revenue streams beyond traditional wholesale distribution.
The deal strengthens an existing retina platform that already generated $600 million in revenue and $75 million in EBITDA in 2022, indicating immediate operational scale.
Integration of all providers onto a unified platform with the existing RCA business is expected to generate significant cost synergies and operational efficiencies.
Diamant Asset Management Inc. significantly increased its stake in Cencora, Inc. (NYSE:COR) by 31,314% during the first quarter, purchasing an additional 291,220 shares to hold a total of 292,150 shares valued at approximately $91.78 million. This filing represents a major institutional accumulation, with Diamant now owning roughly 0.15% of the company's outstanding stock.
The article details various other institutional movements and provides comprehensive financial metrics for Cencora. The company has a market capitalization of $55.83 billion and trades at a P/E ratio of 22.01. Recent analyst activity includes Bank of America raising its price target to $285 with a neutral rating, while UBS raised its target to $412 with a buy rating, reflecting mixed but generally positive market sentiment.
Cencora announced a new share buyback program authorizing the purchase of up to $2.00 billion in shares, representing 3.9% of its outstanding stock, signaling management's confidence in the company's valuation. Additionally, the company recently paid a quarterly dividend of $0.60 per share, resulting in an annualized yield of 0.8% and a low payout ratio of 18.40%. Director Lauren M. Tyler also increased her personal stake by 14.44% in late June.
๐ Diamant Asset Management increased Cencora holdings by 31,314% to $91.78 million.
๐ฐ Cencora authorized a $2.0 billion share buyback program up to 3.9% of shares.
๐ต Quarterly dividend of $0.60 yields 0.8% with an 18.40% payout ratio.
๐ Analysts raised targets: UBS to $412, Bank of America to $285, Morgan Stanley to $342.
๐๏ธ Institutional ownership is 97.52%, trading above the 50-day moving average at $280.84.
๐ Diamant Asset Management Inc. lifted its holdings in Cencora by 31,314% in Q1, buying 291,220 shares to own a total of 292,150 shares valued at $91.78 million.
๐ The company has a market cap of $55.83 billion, trading at a P/E ratio of 22.01 with a price-to-earnings-growth ratio of 1.59.
๐ฐ Cencora declared a $2.00 billion share buyback program authorized by the Board of Directors on May 21st to purchase up to 3.9% of its shares.
๐ต A quarterly dividend of $0.60 was paid on June 1st, representing an annualized yield of 0.8% with a payout ratio of 18.40%.
๐ Bank of America raised its price objective to $285.00 and maintained a neutral rating in a recent research report.
๐ UBS Group increased its target price to $412.00 and assigned a buy rating, while Morgan Stanley set a $342.00 price target.
๐ค Director Lauren M. Tyler purchased 550 shares at an average cost of $270.23, increasing her direct ownership by 14.44% to 4,359 shares.
๐๏ธ Institutional ownership stands at 97.52%, with insider ownership at 0.38% as of the latest filings.
๐ The stock has a fifty-two week range between $244.82 and $377.54, currently trading above its 50-day moving average of $280.84.
๐ฌ Cencora operates as a global healthcare services company providing wholesale drug distribution, specialty pharmacy operations, and cold-chain logistics.
Bullish Signals
Diamant Asset Management increased position by 31,314% to own $91.78 million.
Board approved $2.00 billion share buyback program indicating undervaluation confidence.
Major institutions including Kemnay and Oakworth acquired new stakes in Q4.
Archer Investment Corp grew position by 134.3% adding 47 shares.
Analysts bullish with consensus target price of $367.75 and UBS target at $412.00.
Risk Factors
Weiss Ratings downgraded Cencora to buy (b-).
Bank of America sets $285.00 price target.
Bullish Signals
Diamant Asset Management Inc. executed a massive 31,314% increase in its position, buying nearly one million dollars worth of shares to own $91.78 million of the stock.
The Board of Directors approved a substantial $2.00 billion share buyback program, indicating strong confidence that the current stock price is undervalued relative to intrinsic value.
Major institutional investors like Kemnay Advisory Services, Oakworth Capital, Elyxium Wealth, and Motiv8 Investments all acquired new stakes in the fourth quarter.
Archer Investment Corp grew its position by 134.3% in the fourth quarter, adding 47 shares to its holdings.
Analyst consensus is moderately bullish with twelve Buy ratings versus three Hold ratings, supported by a MarketBeat consensus target price of $367.75.
UBS Group raised its price target to $412.00 and upgraded the sentiment to a buy rating, while Morgan Stanley set a specific target of $342.00.
Risk Factors
Weiss Ratings recently downgraded Cencora from a 'buy (b)' to a 'buy (b-)' rating, indicating a slight reduction in the strength of their positive outlook.
Bank of America maintains a neutral rating with a price target of $285.00, suggesting that some analysts view the current valuation as fair rather than significantly undervalued.
Cencora (COR) stock recently closed at US$286.95, reflecting a 15.3% decline year-to-date but significant gains over the past week and month. The article argues that recent market reassessments of healthcare supply chain companies may be causing an overreaction to Cencora's current valuation.
Using a Discounted Cash Flow (DCF) model based on last twelve months free cash flow of approximately $1.66 billion, the estimated intrinsic value is calculated at US$484.52 per share. This implies a substantial 40.8% discount to the current trading price, suggesting the stock is undervalued relative to its projected future cash flows.
Valuation metrics further support this view, with Cencora trading at a P/E ratio of 21.91x, which is below both the Healthcare industry average of 23.67x and its peer group average of 29.56x. The company's proprietary 'Fair Ratio' is estimated at 24.74x, indicating the stock appears undervalued even when adjusting for specific growth and risk characteristics.
The article concludes that Cencora offers a compelling value proposition with a solid track record and dividend payments, positioning it as a potentially attractive investment despite recent share price weakness compared to peers.
๐ Stock dropped 15.3% YTD but closed at US$286.95 last week.
๐ฐ DCF analysis projects intrinsic value of US$484.52 per share.
๐ Current price offers a 40.8% discount to calculated intrinsic value.
๐ P/E ratio of 21.91x is below industry and peer averages.
๐ฅ Company distributes pharmaceutical products in the US and internationally.
๐ Cencora stock has declined 15.3% year-to-date but gained 5.6% in the past week, closing at US$286.95.
๐ฐ A Discounted Cash Flow (DCF) analysis projects an intrinsic value of US$484.52 per share.
๐ The current price implies a significant 40.8% discount to the calculated intrinsic value based on future cash flows.
๐ Cencora trades at a P/E ratio of 21.91x, which is lower than the industry average of 23.67x and peer average of 29.56x.
๐ The company's proprietary 'Fair Ratio' is estimated at 24.74x, further indicating undervaluation relative to growth and risk profiles.
๐ฅ Cencora sources and distributes pharmaceutical products in the United States and internationally.
๐ต The stock is described as very undervalued with a solid track record and dividend payments.
Bullish Signals
40.8% discount to $484.52 intrinsic value per share.
P/E of 21.91x below industry average of 23.67x.
Solid track record with dividend payments.
Very undervalued with strong fundamentals supporting higher fair value.
Bullish Signals
Cencora's share price implies a 40.8% discount to its estimated intrinsic value of US$484.52 per share based on DCF analysis.
The company trades at a P/E ratio of 21.91x, which is below the Healthcare industry average of 23.67x and peer group average of 29.56x.
Cencora has a solid track record and pays a dividend, adding to its investment appeal.
The stock is described as 'very undervalued' with strong fundamentals supporting a higher fair value.
Cencora Inc. (COR) shares rallied 3.62% to $281.10 on Tuesday, marking a significant outperformance against the broader market which saw the S&P 500 fall 1.44% and the Dow Jones drop slightly. This price increase effectively snapped a three-day losing streak for the pharmaceutical distribution company's stock.
The strong trading session for COR occurred despite a generally rough environment for the wider stock market, highlighting a divergence in investor sentiment specifically toward this ticker compared to major indices like the S&P 500 and Dow Jones Industrial Average.
๐ Cencora shares rose 3.62% to $281.10 on Tuesday.
๐ Rally ended a three-day losing streak for the stock.
๐ S&P 500 fell 1.44% and Dow Jones dropped 0.09%.
๐ COR outperformed competitors during a rough market session.
๐ Cencora Inc. (COR) shares rose 3.62% to close at $281.10 on Tuesday.
๐ The rally ended a three-day losing streak for the company's stock price.
๐ The market-wide decline saw the S&P 500 fall 1.44% and the Dow Jones drop 0.09%.
๐ COR outperformed competitors during an all-around rough trading session for the broader market.
Bullish Signals
Stock rallied 3.62% to $281.10 while S&P 500 fell 1.44%.
Bullish Signals
Cencora Inc. stock rallied 3.62% to $281.10, snapping a three-day losing streak and demonstrating resilience while the broader S&P 500 fell 1.44%.
The company's shares outperformed competitors during a rough trading session, indicating specific investor confidence in COR relative to the wider market.
Cencora (COR) shares closed at $281.43, reflecting a 9.20% gain over the past month but remaining down 16.95% year-to-date. Despite recent momentum rebuilding after a weaker period, the stock trades below analyst fair value estimates of approximately $350.58, suggesting it could be undervalued by roughly 20% based on modeled future cash generation and earnings power.
The company's investment in digital infrastructure and advanced analytics is positioned to capitalize on healthcare digitization and regulatory requirements like the Drug Supply Chain Security Act. These initiatives aim to improve supply chain efficiency and transparency, which analysts believe will drive higher net margins and operating income over time, supported by measured revenue expansion and a potential increase in earnings multiples.
While the margin growth narrative presents significant upside potential, Cencora faces meaningful risks including pressure on margins from lower fee biosimilars and generics, as well as potential regulatory or pricing changes that could compress profitability. The article concludes that investors should weigh these clear risks against the company's solid track record and dividend payments to decide if the current price represents an overlooked entry point.
๐ COR shares down 16.95% YTD despite recent rebound.
๐ฐ Analysts value stock at $350.58, implying 20% undervaluation.
๐ง Digital investments target supply chain efficiency under new rules.
โ ๏ธ Risks include margin pressure from biosimilars and generics.
๐ฆ Solid track record with consistent dividend payments to shareholders.
๐ Cencora (COR) shares closed at $281.43, down 16.95% year-to-date despite a recent 9.20% monthly rebound.
๐ฐ Analysts model a fair value of $350.58, implying the stock is currently undervalued by approximately 20%.
๐ง Strategic investments in digital infrastructure and advanced analytics aim to boost supply chain efficiency under new regulations.
๐ The margin growth narrative relies on measured revenue expansion and a potential lift in profitability metrics.
โ ๏ธ Key risks include margin pressure from lower fee biosimilars, generics, and potential regulatory or pricing changes.
๐ฆ The company maintains a solid historical track record and pays a dividend to shareholders.
Bullish Signals
Stock trades at discount to $350.58 fair value with 20% upside potential.
Digital investments capitalize on healthcare digitization trends and regulatory requirements.
Operational improvements expected to drive higher net margins and operating income.
Solid historical track record and dividend indicate financial stability.
Risk Factors
Margins pressured by lower fee biosimilars and generics.
Regulatory changes could compress profitability and margin growth.
Stock down 16.95% year-to-date showing recent underperformance.
Bullish Signals
The stock trades at a significant discount to its modeled fair value of $350.58, suggesting a potential 20% upside based on future cash generation.
Investments in digital infrastructure and advanced analytics are positioned to capitalize on healthcare digitization trends and regulatory requirements like the Drug Supply Chain Security Act.
These operational improvements are expected to drive higher net margins and operating income over time through improved supply chain efficiency.
The company possesses a solid historical track record and pays a dividend, indicating financial stability.
Risk Factors
Margins face potential pressure from the increasing prevalence of lower fee biosimilars and generic pharmaceutical products.
Regulatory changes or shifts in pricing policies could compress profitability and impact the margin growth narrative.
The stock remains down 16.95% year-to-date, indicating recent underperformance relative to its longer-term positive shareholder returns.
Cencora, Inc. (NYSE: COR) announced a planned leadership transition within its human resources organization effective July 2026. Silvana Battaglia, who served as Executive Vice President and Chief Human Resources Officer for seven years, will retire from her role on July 12, 2026. She will continue to serve as a special advisor through the end of the calendar year to ensure a smooth succession.
Samantha Hammock has been appointed as the new Executive Vice President and Chief Human Resources Officer, effective July 13, 2026. Reporting directly to CEO Bob Mauch, Hammock brings extensive experience from her previous roles at Verizon Communications and American Express. The company highlighted its scale, noting over 51,000 team members and more than $300 billion in annual revenue.
The announcement emphasizes the strategic importance of the CHRO role in shaping productivity, culture, and workforce strategy for this Fortune 500 leader. CEO Bob Mauch praised Battaglia's contributions during a period of significant growth and expressed excitement about Hammock's technology-forward thinking and ability to build high-performing teams as Cencora advances its growth priorities.
๐ Silvana Battaglia retires as EVP/CHRO effective July 12, 2026.
๐ค She transitions to special advisor through year-end for support.
๐ Samantha Hammock joins as new EVP/CHRO effective July 13, 2026.
๐ฐ Cencora operates with over 51,000 employees and $300B revenue.
๐ Company ranks #10 on Fortune 500 and #17 globally.
๐ Silvana Battaglia retires as EVP and CHRO effective July 12, 2026, after a seven-year tenure.
๐ค Battaglia will transition to a special advisor role through year-end to support the new leadership.
๐ Samantha Hammock joins as the new EVP and CHRO effective July 13, 2026.
๐ผ Hammock previously served as CHRO at Verizon Communications and held senior roles at American Express.
๐ Cencora operates with a workforce of over 51,000 team members globally.
๐ฐ The company reported more than $300 billion in annual revenue.
๐ Cencora is ranked #10 on the Fortune 500 and #17 on the Global Fortune 500.
๐ฃ๏ธ CEO Bob Mauch praised Battaglia's global vision and contributions to company culture.
๐ Hammock will focus on workforce transformation and strengthening company culture.
โ The retirement was explicitly stated as not resulting from any operational disagreements.
Bullish Signals
Seasoned CHRO hire signals strong leadership continuity.
Massive scale: 51,000 employees and $300B revenue.
CEO endorses technology-forward HR strategy for growth.
Bullish Signals
The appointment of Samantha Hammock, a seasoned executive with CHRO experience at Verizon and American Express, signals strong leadership continuity and strategic hiring.
Silvana Battaglia's retirement is framed as a planned succession rather than a departure due to conflict, indicating stable internal relations.
Cencora highlights its massive scale with over 51,000 employees and $300 billion in revenue, reinforcing its position as a critical global pharmaceutical solutions provider.
CEO Bob Mauch's endorsement of Hammock's 'technology-forward thinking' suggests the company is actively modernizing its HR strategy to support future growth.
TimesSquare Capital Management released its fourth-quarter 2025 investor letter, highlighting Cencora (NYSE: COR) as a preferred healthcare holding. The firm noted that Cencora's shares gained 8% in the quarter, driven by fiscal Q4 earnings that outpaced consensus estimates due to strength in U.S. operations offsetting an international miss. Management also announced it is considering strategic alternatives for the animal health and non-core segments of its PharmaLex business.
Cencora, a pharmaceutical sourcing and distribution company, closed at $331.74 per share on March 19, 2026, with a market capitalization of approximately $64.5 billion. In the first quarter of fiscal 2026, consolidated revenue increased 5.5% year-over-year to $85.9 billion, reflecting solid growth across both reportable segments. The company is currently held by 61 hedge fund portfolios, an increase from 59 in the previous quarter.
Despite the positive performance and earnings beat, TimesSquare Capital expressed a preference for AI stocks over Cencora for delivering higher returns within a shorter timeframe. While acknowledging the risk and potential of Cencora, the firm believes other sectors may offer superior upside. The article concludes with promotional links to other investment strategies and subscription offers from Insider Monkey.
๐ COR shares rose 8% in Q4 as earnings beat estimates.
๐ฐ Fiscal 2026 Q1 revenue grew 5.5% to $85.9 billion.
๐ข Management considers strategic alternatives for animal health and PharmaLex.
๐ Hedge fund portfolios increased to 61 in Q4 2025.
๐ U.S. strength offset international misses during the quarter.
๐ Cencora (COR) shares rose 8% in Q4 as fiscal fourth-quarter earnings outpaced consensus estimates.
๐ฐ Consolidated revenue for the first quarter of fiscal 2026 increased 5.5% year-over-year to $85.9 billion.
๐ข Management announced it is considering strategic alternatives for animal health and non-core PharmaLex business units.
๐ The stock closed at $331.74 per share on March 19, 2026, with a market cap of $64.5 billion.
๐ Hedge fund holdings increased to 61 portfolios in Q4 2025, up from 59 in the prior quarter.
๐ค TimesSquare Capital prefers AI stocks over Cencora for delivering higher returns and shorter timeframes.
๐ International business missed estimates, though U.S. strength offset this weakness during the quarter.
Bullish Signals
Q4 earnings beat consensus estimates.
Q1 fiscal 2026 revenue rose 5.5% to $85.9B.
U.S. strength offset international miss.
Hedge fund holdings grew from 59 to 61.
Stock gained 8% in Q4 and 24.05% over 52 weeks.
Risk Factors
International operations missed consensus estimates.
The company achieved a 5.5% year-over-year revenue increase in Q1 fiscal 2026 to $85.9 billion.
U.S. business strength successfully offset a miss in international operations during the quarter.
Hedge fund interest is growing, with portfolio holdings increasing from 59 to 61 in Q4 2025.
The stock gained 8% in Q4 and has delivered a 24.05% return over the past 52 weeks.
Risk Factors
International business operations missed consensus estimates, indicating regional weakness.
TimesSquare Capital explicitly states that AI stocks hold greater promise for higher returns than Cencora.
Management is considering strategic alternatives for animal health and non-core PharmaLex segments, which could signal a shift in focus or potential asset divestiture.
Wells Fargo analyst Stephen Baxter maintained an Overweight rating on Cencora, Inc. (NYSE:COR) but lowered its price target to $331 from $429 on May 11, 2026. The firm cited disappointing U.S. healthcare earnings growth as the primary driver for the adjustment, though it noted that Cencora's core growth trends remain aligned with peers like Cardinal Health and McKesson.
Citi also reduced its price target to $355 from $405 on May 7, 2026, while keeping a Buy rating. Both analysts expressed disappointment regarding the fiscal Q2 U.S. healthcare results. Despite these analyst downgrades, Cencora reported adjusted EPS of $4.75 against a consensus of $4.73 and revenue of $78.4B versus an estimate of $81.04B.
CEO Robert P. Mauch stated that the company delivered solid quarterly results with continued execution to support customer needs. The firm highlighted progress in debt reduction during the quarter and plans to resume opportunistic share repurchases in the second half of the fiscal year, citing underlying business strength and a focus on long-term value creation.
Cencora (NYSE:COR) has announced a significant U.S. distribution partnership with Kite Pharma, a subsidiary of Gilead Sciences. The agreement focuses on providing market access and distribution support for FDA-approved CAR T cell therapies across various U.S. treatment centers. This collaboration aims to streamline logistical and administrative processes for healthcare providers administering these complex, personalized cancer treatments.
The deal underscores Cencora's expanding role in the specialized logistics sector for next-generation therapies. Analysts view this partnership as a positive indicator of Cencora's strategic positioning within the growing market for cell and gene therapy distribution. The agreement is expected to influence investor perceptions regarding Cencora's long-term business mix and its relationships with major biopharmaceutical partners.
Financially, Cencora shares are currently trading at $279.57, representing a 25% discount to the consensus analyst target price of approximately $350.58. Simply Wall St valuation models suggest the stock is undervalued by roughly 42.6% relative to its estimated fair value. Recent momentum shows the stock rising 7.1% over the past month, though it has declined 17.5% year-to-date.
๐ค Cencora partners with Kite Pharma for FDA-approved CAR T therapies.
๐ฐ Stock trades at $279.57, 25% below analyst consensus target.
Cencora has entered into an agreement with Kite Pharma to support the US distribution of its two FDA-approved CAR T-cell therapies, Yescarta and Tecartus. The collaboration aims to reduce administrative burdens and expand access to these treatments at authorized treatment centers as Kite expands its network. Cencora will leverage its distribution infrastructure and services to facilitate efficient access and minimize operational friction for community oncology practices and health systems administering the therapies.
The agreement covers both new and existing sites within Kite's treatment center network, with a focus on streamlining order management and supporting a seamless experience across health systems as the network grows. Melissa Lattanzi, vice president of emerging therapies at Cencora, highlighted that cell therapies are individualized treatments requiring precise coordination between treatment centers, manufacturers, and distribution networks to ensure patient outcomes are not compromised by timing issues.
This partnership comes amid industry concerns about whether existing distribution models can handle higher volumes anticipated with broader adoption of cell and gene therapies. Cencora is investing $1 billion in infrastructure through 2030, including a new national distribution center in Ohio with advanced automation and cold-chain capacity. Christophe Griolet, US vice president at Kite, emphasized that the goal is to ensure every appropriate patient can access and benefit from these treatments by reducing provider barriers.
The Cencora-Kite agreement signals a shift in how cell and gene therapies are commercialized, where specialty distributors play a central role in reducing institutional friction between treatment availability and patient access. As CAR T-cell therapy expands into more community settings, the ability to absorb administrative complexity at the distributor level will become a competitive differentiator for manufacturers choosing commercial partners.
๐ค Cencora partners with Kite to distribute Yescarta and Tecartus therapies.
โฑ๏ธ Delays cause 65% of patients to deteriorate before CAR T administration.
๐ฐ Cencora invests $1B by 2030 in automated cold-chain distribution centers.
๐ค Cencora has entered an agreement with Kite to support US distribution of Yescarta and Tecartus CAR T-cell therapies.
๐ฅ The collaboration aims to expand access at authorized treatment centers by leveraging Cencora's distribution infrastructure.
๐ A key goal is reducing administrative burdens and operational friction for community oncology practices and health systems.
๐งฌ CAR T-cell therapies are autologous treatments requiring precise coordination between treatment centers, manufacturers, and distributors.
โฑ๏ธ A January 2026 analysis found that 65% of community oncologists reported patients deteriorate before CAR T administration due to delays.
๐ Major obstacles to timely CAR T evaluation include travel distance, affordability, and prior authorization delays identified in a national survey.
๐ฆ Cencora's role includes managing order processes and supporting seamless experiences across new and existing sites in Kite's network.
๐ผ Melissa Lattanzi of Cencora stated the partnership advances Kite's goal to bring therapies closer to patients' homes.
๐ฃ๏ธ Christophe Griolet of Kite emphasized that Cencora's expertise will reduce provider barriers and meet patients where they are.
๐ Industry panelists at the 2026 Asembia summit questioned if current distribution models are ready for higher CGT volumes.
๐ฐ Cencora is executing a $1 billion infrastructure investment through 2030 to support complex therapy capabilities.
๐ญ This investment includes a planned 530,000 square-foot national distribution center in Ohio with advanced automation and AI.
โ๏ธ The new facility features expanded cold-chain capacity essential for storing sensitive cell therapies.
๐ The agreement signals a shift where specialty distributors play a central role in reducing institutional friction for patients.
๐ As CAR T-cell therapy expands, the ability to absorb administrative complexity at the distributor level will become a competitive differentiator.
Risk Factors
Panelists question if distribution/payment models handle higher CGT volumes.
65% of oncologists report patient deterioration before CAR T due to payer delays.
Travel, affordability, and prior auth delays top five CAR T evaluation obstacles.
Risk Factors
Industry panelists at the 2026 Asembia specialty pharmacy summit questioned whether existing distribution and payment models are ready for higher volumes anticipated with broader CGT adoption.
A January 2026 analysis reported that 65% of community oncologists noted patients deteriorate before CAR T administration, with payer approval timelines cited as a rate-limiting factor.
A national survey identified travel distance, ability to travel for evaluation, caregiver requirements, affordability, and prior authorization delays as the top five obstacles to timely CAR T evaluation.
Cencora (COR) announced on May 27, 2026, the appointment of Eva C. Boratto as its new Executive Vice President and Chief Financial Officer, effective June 29, 2026. She succeeds retiring CFO James F. Cleary, who will transition to an advisory role through year-end to ensure continuity. Boratto brings extensive experience from senior roles at Bath & Body Works, CVS Health, and Merck, along with audit committee chair positions at Mars and UPS, strengthening Cencora's financial leadership as it pursues its pharmaceutical-centric growth strategy.
Alongside the leadership change, Cencora reaffirmed its adjusted diluted earnings per share guidance of $17.70 to $17.90 for fiscal 2026, a figure updated on May 21, 2026, following opportunistic share repurchases. The company reiterated long-term targets for adjusted operating income growth of 7% to 10% and adjusted EPS growth of 10% to 14%. This reaffirmed outlook signals management's confidence in the company's current trajectory and suggests that the CFO transition is not expected to disrupt financial performance or long-term value-creation plans for shareholders.
Cencora is a leading global pharmaceutical solutions organization ranked No. 10 on the Fortune 500, generating more than $300 billion in annual revenue from its pharmaceutical-centric operations. Operating at the center of the global pharmaceutical supply chain, the company partners with drug innovators and care providers to facilitate market access to therapies and ensure secure delivery of pharmaceuticals and healthcare products for people and animals. Its business model positions it as a critical intermediary between manufacturers and providers, underpinning its scale-driven margins and ability to pursue steady, long-term earnings growth.
๐ฉโ๐ผ Eva Boratto appointed CFO effective June 29, 2026, succeeding retiring James Cleary.
๐ฐ Cencora reaffirmed FY2026 EPS guidance of $17.70โ$17.90 and long-term growth targets.
๐ Stock rated Buy by analysts with a $331 target despite current downtrend.
๐ฉโ๐ผ Cencora appointed Eva C. Boratto as Executive Vice President and Chief Financial Officer, effective June 29, 2026.
๐ She succeeds retiring CFO James F. Cleary, who will stay in an advisory role through year-end to ensure continuity.
๐ฅ Boratto brings extensive experience from senior roles at Bath & Body Works, CVS Health, and Merck.
๐ฐ Cencora reaffirmed its adjusted diluted earnings per share guidance of $17.70 to $17.90 for fiscal 2026.
๐ The company reiterated long-term targets for adjusted operating income growth of 7% to 10%.
๐ Management also maintained an adjusted EPS growth target of 10% to 14% for the long term.
๐ค The CFO transition is not expected to disrupt financial performance or shareholder value creation plans.
๐ Analysts currently rate Cencora stock as a Buy with a $331.00 price target.
โ๏ธ AI Analyst Spark rates COR as Neutral due to solid operations offset by balance-sheet leverage risk.
๐ Technical indicators show a clear downtrend and weak momentum for the stock.
๐ต Valuation is considered a relative positive due to the low P/E ratio.
๐ Cencora is ranked No. 10 on the Fortune 500 and generates over $300 billion in annual revenue.
๐ฆ The company operates as a critical intermediary between pharmaceutical manufacturers and healthcare providers.
๐ Its business model focuses on logistics, distribution, and ensuring secure delivery of healthcare products.
Bullish Signals
Cencora appoints experienced Eva C. Boratto as new CFO.
Company reaffirms 2026 EPS guidance of $17.70 to $17.90.
Management reiterates long-term operating income growth targets of 7% to 10%.
Cencora ranked No. 10 on Fortune 500 with over $300B revenue.
Valuation is positive due to low P/E ratio.
Risk Factors
Balance-sheet leverage risk identified.
Free cash flow deteriorated.
Bullish Signals
Cencora appointed Eva C. Boratto as new CFO, bringing extensive experience from senior roles at Bath & Body Works, CVS Health, and Merck to bolster its financial leadership.
The company reaffirmed adjusted diluted earnings per share guidance of $17.70 to $17.90 for fiscal 2026 following opportunistic share repurchases.
Management reiterated long-term targets for adjusted operating income growth of 7% to 10% and adjusted EPS growth of 10% to 14%, signaling confidence in sustained performance.
The CFO transition is not expected to disrupt financial performance or long-term value-creation plans for shareholders.
Cencora is ranked No. 10 on the Fortune 500 and generates more than $300 billion in annual revenue from its pharmaceutical-centric operations.
Valuation is a relative positive due to the low P/E ratio, despite other technical factors.
Risk Factors
Meaningful balance-sheet leverage risk is identified as a concern.
Wells Fargo analyst Stephen Baxter has reiterated his Buy rating on Cencora (COR), setting a price target of $331.00, which is lower than the previous target of $429. The company's shares closed at $267.01 prior to the report. Baxter covers the Healthcare sector and includes Cencora alongside peers like McKesson and Elevance Health in his coverage.
The broader market sentiment remains positive for Cencora, with a strong Buy consensus rating and an average price target of $358.40 across analysts, implying 34.23% upside from current levels. TD Cowen also recently reiterated a Buy rating with a $400.00 price target in a report released on May 11.
Cencora reported strong financial results for the quarter ending March 31, with revenue reaching $78.36 billion and net profit of $1.64 billion, compared to $75.45 billion in revenue and $717.87 million in profit a year ago. The company maintains its long-term adjusted EPS growth outlook between 10% and 14%.
๐ Wells Fargo maintains Buy on Cencora with $331 price target.
๐ฐ Q1 revenue hit $78.36B with net profit of $1.64B.
๐ฏ Street consensus is Strong Buy averaging $358.40 upside potential.
๐ฎ FY26 EPS guidance narrowed to $17.70-$17.90 range.
๐ Long-term adjusted EPS growth projected between 10%-14%.
๐ Wells Fargo analyst Stephen Baxter reiterates a Buy rating on Cencora with a new price target of $331.00.
๐ The analyst lowered the price target from $429, though it remains above the current stock price of $267.01.
๐ฐ Cencora reported quarterly revenue of $78.36 billion and net profit of $1.64 billion for the quarter ended March 31.
๐ Year-over-year growth is evident with revenue increasing from $75.45 billion and net profit rising to $1.64 billion.
๐ฏ The Street maintains a Strong Buy consensus with an average price target of $358.40, suggesting 34.23% upside.
๐ฎ Cencora backs its FY26 adjusted EPS view at $17.70-$17.90, narrowing slightly from previous guidance.
๐ The company projects long-term adjusted EPS growth of 10%-14% for the foreseeable future.
๐ TD Cowen also supports the stock with a Buy rating and a $400.00 price target set in May.
Bullish Signals
Analyst Stephen Baxter maintains a Buy rating on Cencora.
Revenue grew from $75.45B to $78.36B in latest quarter.
Net profit doubled from $717.87M to $1.64 billion.
Strong Buy consensus with average price target of $358.40.
TD Cowen targets $400.00 with reiterated Buy rating.
Long-term adjusted EPS growth outlook stands at 10%-14%.
Risk Factors
Wells Fargo lowered target from $429 to $331.
Current price $267.01 is below average target $358.40.
Bullish Signals
Wells Fargo analyst Stephen Baxter maintains a Buy rating on Cencora, indicating continued confidence in the company's fundamentals.
Cencora achieved significant year-over-year growth with revenue increasing from $75.45 billion to $78.36 billion in the latest quarter.
Net profit more than doubled from $717.87 million last year to $1.64 billion, demonstrating strong operational efficiency.
The broader analyst consensus is a Strong Buy with an average price target of $358.40, implying substantial upside potential.
TD Cowen recently reiterated a Buy rating with a high $400.00 price target, reinforcing positive market sentiment.
Cencora maintains a robust long-term adjusted EPS growth outlook of 10%-14%, signaling sustained profitability expansion.
Risk Factors
Wells Fargo analyst Stephen Baxter lowered the price target from $429 to $331, indicating some caution or adjustment in valuation expectations.
The current stock price of $267.01 is significantly below the average analyst price target of $358.40, suggesting potential volatility if targets are not met.
Cencora (NYSE:COR) reported strong fiscal second-quarter results with adjusted diluted earnings per share rising 7.5% to $4.75, driven by higher operating income and robust revenue performance across its segments. Management raised its full-year adjusted EPS outlook while lowering full-year revenue growth expectations, attributing the latter to a large mail-order pharmacy customer converting brands faster than anticipated and slower-than-expected growth in GLP-1 products. The company also announced it would resume opportunistic share repurchases following strong cash generation.
Consolidated revenue increased 4% year-over-year to $78.4 billion, with adjusted gross profit growing 16% to $3.4 billion and gross margin expanding 45 basis points to 4.31%. The margin expansion was partially attributed to the acquisition of OneOncology in February 2026, which contributed $36 million to net interest expense as the company raised debt to finance the deal. Adjusted consolidated operating income grew 6% to $1.3 billion, though this figure included one-time headwinds from a lost oncology customer and inclement weather events that reduced patient appointments.
The U.S. Healthcare Solutions segment reported revenue growth of 3% to $68.8 billion, with GLP-1 sales contributing $1.9 billion year-over-year despite being offset by manufacturer list price reductions totaling $2 billion in headwinds. Operating income in the U.S. rose 6% to $998 million, excluding impacts from a lost oncology customer and weather-related disruptions that collectively estimated a combined operating income headwind of approximately $20 million. International Healthcare Solutions revenue surged 13% to $7.6 billion, driven by European distribution and specialty logistics rebounds, while the "other" category saw revenue growth primarily from Profarma and MWI Animal Health following the divestiture of legacy U.S. hub consulting services in late April.
Cencora ended the quarter with $2.2 billion in cash after generating $1.1 billion in free cash flow, maintaining its full-year adjusted free cash flow guidance at approximately $3 billion. CEO Bob Mauch highlighted the company's resilience and confidence in fiscal 2026, emphasizing strategic investments in the pharmaceutical supply chain including cell and gene therapies logistics. CFO Jim Cleary noted that excluding the acquisition and customer loss impacts, U.S. segment growth would have been around 7%, aligning with long-term targets despite near-term operational challenges.
Cencora raised full-year EPS outlook while reporting $4.75 adjusted diluted earnings per share.
Consolidated revenue grew 4% to $78.4B, boosted by strong U.S. and international performance.
Operating expenses rose 22.5%, driven partly by debt for the OneOncology acquisition.
Management maintains full-year free cash flow guidance at approximately $3 billion.
- ๐ Cencora reported higher Q2 adjusted earnings and operating income while raising its full-year adjusted EPS outlook.
- ๐ฐ The company resumed opportunistic share repurchases and highlighted resilience in both U.S. and International Healthcare Solutions segments.
- ๐ Full-year revenue growth expectations were lowered due to faster-than-expected brand conversions at a major mail-order pharmacy customer and slower anticipated GLP-1 product growth.
- ๐จโ๐ผ CEO Bob Mauch noted that investments in the pharmaceutical supply chain are enabling the company to capitalize on key growth opportunities.
- ๐ต Adjusted diluted EPS reached $4.75, representing a 7.5% increase year-over-year compared to the prior quarter.
- ๐ฆ Consolidated revenue grew 4% to $78.4 billion, driven by growth across all reportable segments and the "other" category.
- ๐ข Adjusted consolidated gross profit climbed 16% to $3.4 billion with a gross profit margin expansion of 45 basis points.
- ๐ฅ The margin increase was primarily attributed to the February 2026 acquisition of OneOncology.
- ๐ธ Operating expenses rose 22.5% overall but grew only 5% on a constant-currency basis excluding management services organizations.
- ๐ Net interest expense increased $36 million year-over-year to $140 million due to debt raised to finance the OneOncology acquisition.
- ๐บ๐ธ U.S. Healthcare Solutions revenue rose 3% to $68.8 billion, led by $1.9 billion in growth from GLP-1 sales.
- โ ๏ธ U.S. growth was tempered by a $2 billion headwind from manufacturer list price reductions and the loss of key oncology and grocery customers in fiscal 2025.
- ๐ง๏ธ Inclement weather caused a $10 million operating income headwind in late January and early February due to missed patient appointments.
- ๐ COVID-19 vaccine contributions were down by $10 million compared to the prior-year quarter, offsetting some growth potential.
- ๐ International Healthcare Solutions revenue increased 13% year-over-year to $7.6 billion, primarily driven by European distribution business.
- ๐ Global specialty logistics delivered a second consecutive quarter of operating income growth aided by a rebound in developing markets.
- ๐งฌ The company is winning new contracts for complex specialty products like cell and gene therapies, leveraging its global reach.
- ๐พ Revenue in the "other" category grew 5% to $2.1 billion, largely fueled by growth at Profarma and MWI Animal Health.
- ๐ Operating income in the "other" category declined 1% to $92 million due to an expected decline from legacy U.S. hub consulting services.
- ๐ฐ The company ended March with $2.2 billion in cash after generating $1.1 billion of free cash flow during the quarter.
- ๐ฏ Management maintained its full-year adjusted free cash flow guidance of approximately $3 billion despite market fluctuations.
Bullish Signals
Cencora earnings beat expectations with strong resilience.
Management raised full-year adjusted EPS outlook for 2026.
Company resumed opportunistic share repurchases for value return.
Diluted EPS grew 7.5% to $4.75 year-over-year.
Consolidated revenue rose 4% to $78.4 billion total.
Gross profit increased 16% with margin expansion of 45 bps.
Company generated $2.2 billion cash and $1.1 billion free cash flow.
International revenue grew 13% while operating income rose 14%.
U.S. sales surged due to GLP-1 segment growth.
Cencora secured new contracts in cell and gene therapies.
Adjusted EPS outlook remains strong at ~$20 per share.
Risk Factors
Faster brand conversions concentrate revenue on low-margin sales.
Manufacturer list price reductions caused a $2 billion revenue headwind.
Management raised its full-year adjusted EPS outlook, signaling strong confidence in the company's performance for fiscal 2026.
The company announced it would resume opportunistic share repurchases, highlighting a commitment to returning value to shareholders.
Adjusted diluted EPS grew by 7.5% year-over-year to $4.75, driven by growth in both U.S. and International Healthcare Solutions segments.
Consolidated revenue rose 4% to $78.4 billion, reflecting strong volume growth across both reportable segments.
Adjusted consolidated gross profit increased 16% to $3.4 billion, with the gross profit margin expanding 45 basis points to 4.31%.
The company generated $2.2 billion in cash and produced $1.1 billion of free cash flow during the quarter.
Cencora maintained its full-year adjusted free cash flow guidance of approximately $3 billion, validating its cash generation capabilities.
U.S. Healthcare Solutions saw $1.9 billion of year-over-year growth specifically from GLP-1 sales.
International Healthcare Solutions revenue increased 13% to $7.6 billion, with operating income rising 14% to $176 million.
The International segment delivered its second consecutive quarter of operating income growth, driven by a rebound in European distribution and specialty logistics.
Cencora is winning new specialty logistics contracts in high-growth areas like cell and gene therapies and laboratory logistics.
Revenue in the "other" category rose 5% to $2.1 billion, driven by growth at Profarma and MWI Animal Health.
Risk Factors
Cencora lowered its full-year revenue growth expectations due to faster-than-anticipated brand conversions at a large mail-order pharmacy customer, which weighs on revenue more than expected and concentrates the effect on low-margin sales.
A $2 billion revenue headwind in the quarter stemmed from manufacturer list price reductions.
Cencora continues to face the impact of previously disclosed fiscal 2025 customer losses for both an oncology client and a grocery customer, with the oncology loss remaining larger than the contribution from the February 2026 OneOncology acquisition during the quarter.
Inclement weather across the U.S. in late January and early February led to missed patient appointments and lower physician office volumes, creating an estimated $10 million operating income headwind.
COVID-19 vaccines contributed a negative $10 million to operating income compared with a $15 million contribution in the prior-year quarter.
Legacy U.S. hub consulting services are expected to decline in revenue following Cencora's divestiture on April 30, causing operating income in the 'other' category to fall 1% to $92 million.
Glancy Prongay Wolke & Rotter LLP has announced the commencement of an investigation into Cencora, Inc. (NYSE: COR) regarding potential violations of federal securities laws affecting investors. The firm is seeking to represent shareholders who may have suffered financial losses due to alleged corporate misconduct related to the company's recent operational challenges and earnings disclosures.
The investigation stems from events occurring on May 6, 2026, when Cencora reported its second-quarter 2026 financial results, revealing a revenue of $78.3 billion that missed consensus estimates by $2.68 billion. During the earnings call, management highlighted that manufactured list price reductions created a significant negative impact, acting as a $2 billion revenue headwind for the quarter. In response to these disappointing figures and revised full-year 2026 revenue growth guidance lowered from an expectation of 7% to 9%, Cencora's stock price dropped sharply by 17.4%, or $53.16, to close at $252.74 per share on May 6, 2026.
The press release includes details for potential class action participation, providing a contact for legal inquiries including Charles Linehan of the law firm via email and telephone. The text also notes the firm's qualifications, citing recognition as a Securities Group of the Year by Law360 and highlighting its history of investor recoveries, while noting that past results do not guarantee future outcomes.
๐ผ Law firm Glancy investigates Cencora for federal securities violations.
๐ Stock dropped 17.4% after Q2 revenue missed estimates by $2.68B.
โ ๏ธ Shareholders can contact the firm to inquire about recovering losses.
๐ Law firm Glancy Prongay Wolke & Rotter LLP has announced it is investigating potential federal securities law violations by Cencora, Inc. (NYSE: COR).
๐ The investigation was prompted by the company's May 6, 2026 second-quarter financial results which significantly missed analyst expectations.
๐ฐ Cencora reported Q2 revenue of $78.3 billion, missing consensus estimates by a substantial margin of $2.68 billion.
โฌ๏ธ Management reduced its full-year 2026 revenue growth guidance to 4%โ6%, down from a prior range of 7%โ9%.
๐ The company disclosed that manufactured list price reductions acted as a $2 billion headwind to revenue in the quarter.
๐ Cencora's stock price dropped sharply by $53.16, or 17.4%, closing at $252.74 per share on May 6, 2026.
โ ๏ธ Investors who lost money are urged to contact the law firm to inquire about potentially pursuing claims to recover their losses.
๐ Interested parties can reach Charles Linehan, Esq., via email at [email protected] or toll-free at 888-773-9224.
โ๏ธ Persons with non-public information about Cencora are being asked to consider contacting the firm or utilizing the SEC Whistleblower Program.
๐ The law firm, GPWR, is noted for ranking second-highest in total investor recoveries by Institutional Shareholder Services in 2025.
Bullish Signals
Cencora reported Q2 2026 revenue of $78.3 billion.
Glancy Prongay Wolke ranked top in investor recoveries for 2025.
SEC whistleblowers may receive rewards up to 30%.
Firm encourages cooperation with SEC Whistleblower Program.
Risk Factors
Ongoing securities fraud investigation into Cencora (NYSE: COR).
Huge Q2 2026 miss of $2.68 billion revenue.
Fiscal year 2026 growth guidance slashed to 4%.
$2 billion headwind from list price reductions.
Stock crashed 17.4% amid severe investor concern.
Bullish Signals
Cencora reported Q2 2026 revenue of $78.3 billion, providing a substantial absolute revenue figure despite the miss in consensus estimates.
The firm handling the investigation, Glancy Prongay Wolke & Rotter LLP, was named Law360's Securities Group of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025, indicating strong historical success in recovering funds for shareholders.
Potential whistleblowers under the SEC Whistleblower Program may receive rewards totaling up to 30 percent of any successful recovery made by the SEC, offering an opportunity for information contributors.
The law firm encourages persons with non-public information to contact them or take advantage of the SEC Whistleblower Program, suggesting transparency and cooperation channels remain open.
Risk Factors
An ongoing securities fraud investigation into Cencora, Inc. (NYSE: COR) suggests potential violations of federal securities laws.
Cencora's second quarter 2026 financial results missed consensus estimates by a massive $2.68 billion on revenue of $78.3 billion.
Management drastically reduced full year 2026 revenue growth guidance from 7% to 9% down to only 4% to 6%.
A specific headwind of $2 billion was identified due to 'manufactured list price reductions' impacting the quarter.
The stock price crashed, falling $53.16 or 17.4% on May 6, 2026, indicating severe investor concern and loss.
Potential investors who lost money are being urged to pursue claims for recovery, implying significant financial harm has already occurred.
Law Offices of Howard G. Smith has announced an ongoing securities fraud investigation targeting investors in Cencora, Inc. (NYSE: COR). The firm is seeking to represent shareholders who may have suffered financial losses due to alleged violations of federal securities laws and is inviting potential claimants to contact them via phone, email, or their website for more information regarding their legal rights.
The allegations center on events surrounding May 6, 2026, when Cencora released its second-quarter 2026 financial results showing significant missed expectations. Specifically, the company reported revenue of $78.3 billion, which fell short of consensus estimates by a substantial $2.68 billion. Additionally, management revised their full-year 2026 revenue growth guidance downward from an expected 7% to 9% to a range of 4% to 6%.
On the earnings call, Cencora management attributed part of the poor performance to a specific operational headwind, revealing that manufactured list price reductions resulted in a $2 billion revenue drag for the quarter. This negative news triggered a sharp decline in the company's stock price on May 6, 2026, with shares dropping by $53.16, or 17.4%, to close at $252.74 per share. The law firm asserts that this market decline injured investors and is seeking to aggregate their claims for recovery.
๐ Cencora missed Q2 revenue estimates by $2.68 billion due to price reductions.
โฌ๏ธ Management lowered full-year growth guidance from 7โ9% to just 4โ6%.
๐ Stock price plummeted 17.4%, closing at $252.74 following the report.
๐ Potential investors may contact the firm to explore legal claims regarding losses.
โ๏ธ Law Offices of Howard G. Smith is announcing an investigation into potential securities law violations regarding Cencora, Inc. (NYSE: COR).
๐ The firm encourages investors who suffered losses in Cencora stock to contact them about potentially pursuing claims to recover their investment.
๐ Shareholders are instructed to reach out via email, telephone at (215) 638-4847, or the website www.howardsmithlaw.com for more information.
๐ On May 6, 2026, Cencora reported its second quarter 2026 financial results showing revenue of $78.3 billion.
โ The reported revenue missed consensus estimates by a significant margin of $2.68 billion.
โฌ๏ธ Management reduced the full year 2026 revenue growth guidance from a range of 7% to 9% down to 4% to 6%.
๐ค During the earnings call, management cited "manufactured list price reductions" as causing a $2 billion headwind to quarterly revenue.
๐ In response to the disappointing news, Cencora's stock price dropped $53.16 or 17.4% to close at $252.74 per share on May 6, 2026.
โ ๏ธ The press release notes that this announcement may be considered attorney advertising in some jurisdictions under applicable laws and rules.
Bullish Signals
Cencora posted Q2 2026 revenue of $78.3 billion.
Company secured significant presence despite recent challenges.
Risk Factors
Revenue missed estimates by $2.68B in Q2 2026.
Full year 2026 guidance slashed from 7-9% to 4-6%.
$2B revenue headwind caused by price reductions.
Shares dropped 17.4% to $252.74.
Bullish Signals
Cencora, Inc. (COR) reported $78.3 billion in revenue for the second quarter of 2026.
Despite recent challenges, Cencora has established a significant presence in the healthcare supply chain.
Risk Factors
Cencora's second quarter 2026 revenue of $78.3 billion significantly missed consensus estimates by $2.68 billion, indicating severe operational or reporting issues.
The company reduced its full year 2026 revenue growth guidance from 7% to 9% down to a lower range of 4% to 6%, signaling deteriorating future performance expectations.
Management disclosed that manufactured list price reductions created a $2 billion revenue headwind for the quarter, highlighting a substantial drag on top-line growth.
Shares plummeted 17.4% ($53.16) following the earnings release, closing at $252.74 per share on May 6, 2026, reflecting a significant loss of market confidence and value for investors.
The Law Offices of Frank R. Cruz has announced a securities fraud investigation into Cencora, Inc. (NYSE: COR) on behalf of shareholders who may have lost money due to potential violations of federal securities laws. The firm specifically targets investors who purchased the stock around the time of significant negative developments in the second quarter of 2026, urging them to contact the law firm if they wish to inquire about pursuing a claim to recover losses.
The investigation is triggered by Cencora's financial results released on May 6, 2026, which showed a substantial miss against consensus estimates and a significant downward revision in guidance. The company reported Q2 revenue of $78.3 billion, which was $2.68 billion lower than expected, and slashed its full-year 2026 revenue growth guidance from a range of 7% to 9% down to 4% to 6%. Management attributed a $2 billion revenue headwind during the quarter to manufactured list price reductions in their pharmaceutical segments.
Immediately following the earnings announcement on May 6, 2026, Cencora's stock price plummeted by 17.4%, or $53.16 per share, closing at $252.74. The law firm frames this sharp decline as an injury to investors caused by the company's disclosure of these issues, specifically highlighting the revelation that manufactured list price reductions represented a massive negative financial impact. Interested parties are instructed to provide their mailing address, telephone number, and number of shares purchased when contacting the legal team at 310-914-5007 or via email at [email protected] for more information regarding the potential claims.
๐ Shares dropped 17.4% after revenue missed estimates by $2.68 billion due to list price cuts.
๐ Full year growth guidance was lowered from 7-9% to a range of 4-6%.
โ ๏ธ A securities fraud investigation has been launched regarding the company's reported financial results.
๐ Cencora (NYSE: COR) announced a significant stock drop on May 6, 2026, with shares falling $53.16 or 17.4% to close at $252.74 per share.
๐ฐ The company reported second quarter 2026 revenue of $78.3 billion, which missed consensus estimates by $2.68 billion.
๐ Management revised full year 2026 revenue growth guidance downward to a range of 4% to 6%, down from the previous 7% to 9%.
โ ๏ธ During the earnings call, executives disclosed that manufactured list price reductions created a $2 billion revenue headwind for the quarter.
๐ The alleged securities fraud investigation was initiated by The Law Offices of Frank R. Cruz on behalf of affected investors.
๐ The law firm is investigating potential violations of federal securities laws related to Cencora's reported financial results and stock performance.
๐ต Shareholders who suffered financial losses are being urged to contact the firm to inquire about potentially pursuing a claim for recovery.
๐ Interested parties can contact The Law Offices of Frank R. Cruz at 310-914-5007 or via email at [email protected].
๐ The law firm's physical address is located at 2121 Avenue of the Stars, Suite 800 in Century City, California 90067.
๐ Those contacting the firm by email are requested to include their mailing address, telephone number, and number of shares purchased.
โ๏ธ The press release includes a disclaimer stating it may be considered Attorney Advertising in some jurisdictions under applicable laws.
๐ Further updates regarding this investigation can be followed on the law firm's Twitter account at twitter.com/FRC_LAW.
๐ A source version of the announcement is available for viewing on businesswire.com.
๐ข The news was originally distributed via a press release dated May 8, 2026, through Technology Marketing Corporation.
Bullish Signals
Cencora Q2 2026 revenue reached $78.3B.
Stock trades at $252.74 on May 6, 2026.
Risk Factors
Revenue missed Q2 2026 estimates by $2.68 billion.
Manufactured list price cuts caused a $2 billion revenue drag.
Full year 2026 growth guidance lowered to 4%-6%.
Stock fell 17.4% on May 6, 2026.
Facing securities fraud investigation and legal claims.
Bullish Signals
Cencora, Inc. (COR) reported second quarter 2026 revenue of $78.3 billion, demonstrating significant scale and market presence.
Despite missing consensus estimates, the company's stock price remains at $252.74 per share as of May 6, 2026, providing a current valuations context for potential investors.
Risk Factors
Cencora missed Q2 2026 consensus revenue estimates by a significant $2.68 billion, trading at $78.3 billion total.
Management explicitly disclosed that manufactured list price reductions acted as a $2 billion revenue headwind for the quarter, suggesting structural pressure on earnings.
The company downgraded its full year 2026 revenue growth guidance range to 4% to 6%, a reduction from the prior outlook of 7% to 9%.
The stock price plummeted by 17.4%, dropping $53.16 per share to close at $252.74 on May 6, 2026, following the announcement of these poor results.
Investors are being urged to pursue legal claims due to an announced Securities Fraud investigation into Cencora's possible violations of federal securities laws.
Cencora, Inc., operating as a leading provider of healthcare distribution solutions, announced its fiscal year 2026 earnings guidance and strategic capital allocation updates on May 6, 2026. The company projected diluted earnings per share (EPS) for the full fiscal year 2026 to fall between $17.65 and $17.90, reflecting strong operational performance across its business segments. During the discussion of Q2 fiscal 2026 results, Robert Mauch, representing Cencora leadership, highlighted that the company achieved operating income growth in both its U.S. and International Healthcare Solutions segments. This growth was accompanied by a reported 7.5% year-over-year increase in adjusted diluted EPS, underscoring sustained profitability and effective margin management despite broader market dynamics.
In addition to earnings guidance, Cencora confirmed the immediate resumption of share repurchases with an authorization level of $1 billion. Management framed this decision as part of an "opportunistic" buyback program, signaling confidence in the company's balance sheet and cash flow generation capabilities. This move aims to return value to shareholders while maintaining flexibility to adjust the pace of repurchases based on market conditions. The earnings release also reinforced the company's long-term growth strategy driven by its diversified portfolio and expanding footprint in healthcare distribution services.
The announcement reflects positive momentum in Cencora's core operations, particularly as it navigates evolving supply chain and pricing environments within the healthcare sector. Investors are likely to view the combination of solid EPS growth and renewed dividend support through share buybacks as a vote of confidence in future cash flows. The guidance of $17.65-$17.90 suggests disciplined execution toward maintaining industry-leading margins, while the $1 billion repurchase program offers a clear financial commitment to shareholder returns beyond just earnings growth.
๐ U.S. and International operating income grew in Q2 fiscal 2026.
๐ฐ $1 billion share repurchase program resumed after previous pause.
๐ฎ FY2026 EPS guidance set between $17.65 and $17.90.
๐ Robert Mauch reported operating income growth across both U.S. and International Healthcare Solutions segments during the second quarter of fiscal 2026.
๐ Adjusted diluted earnings per share increased by 7.5% compared to the prior year period.
๐ฐ Cencora announced it is resuming its opportunistic share repurchase program with a target of $1 billion.
๐ฎ Management provided a forward-looking guidance range for FY2026 EPS between $17.65 and $17.90 per share.
๐ The earnings call insights were released on May 6, 2026.
โ ๏ธ This article is an AI-generated summary based on content from Seeking Alpha and has not been reviewed for accuracy.
Bullish Signals
Cencora EPS grew 7.5% in Q2 fiscal 2026.
Operating income rose in U.S. and International segments.
Company resumes share repurchases with $1B commitment.
Management signals confidence in its capital position.
Risk Factors
Article is AI-generated by a tool.
Seeking Alpha does not guarantee accuracy.
No human review before publication.
Seeking Alpha is not a licensed dealer.
Financial figures like FY2026 EPS need caution.
Bullish Signals
Cencora reported adjusted diluted EPS growth of 7.5% for Q2 fiscal 2026, driven by operating income increases in both its U.S. and International Healthcare Solutions segments.
The company announced the resumption of opportunistic share repurchases with a commitment to return $1 billion to shareholders, signaling confidence in its capital position.
Risk Factors
The article explicitly states it was automatically generated by an AI tool based on content available on the Seeking Alpha website.
Seeking Alpha does not guarantee the accuracy, completeness, or timeliness of such articles due to inherent limitations in using AI-based tools.
Neither the AI-generated summary nor the provided text has been curated or reviewed by humans before publication.
The article contains a significant disclaimer stating that Seeking Alpha is not a licensed securities dealer, broker, US investment adviser, or investment bank.
The content lacks human verification, meaning any financial figures or outlooks presented (such as the FY2026 EPS guidance) should be treated with caution and cross-verified against official press releases or transcripts.
Cencora (COR) reported Q2 2026 results that missed both earnings per share and revenue estimates. The company posted adjusted earnings of $4.75 per share, slightly below the Zacks Consensus Estimate of $4.80, marking a negative earnings surprise of -1.04%. Revenue for the quarter ended March 2026 was $78.36 billion, which fell short of the estimated $80.61 billion by 2.98%. Year-over-year growth saw earnings increase to $4.75 from $4.42 a year prior, while revenue climbed from $75.45 billion. This marks the second consecutive quarter of missing estimates after beating them three times in the previous four quarters.
Despite the miss, Cencora's stock underperformed the broader market, declining approximately 9.4% year-to-date compared to the S&P 500's gain of 6%. The article notes that future price movements will largely hinge on management's commentary during the earnings call and subsequent trends in analyst estimates. Currently, the mixed estimate revisions ahead of the report have translated Cencora into a Zacks Rank #3 (Hold), suggesting the stock may perform in line with the market until consensus forecasts are updated.
Looking ahead, the consensus EPS estimate for the coming quarter is set at $4.35 on projected revenues of $87.24 billion, while the full-year fiscal year consensus stands at $17.58 per share on $346.07 billion in revenue. The analysis highlights that the medical services industry as a whole remains in the top 39% of Zacks-ranked industries, which historically outperforms the bottom half by a factor of more than 2 to 1. The report also mentions peer Concentra Group (CON) is set to report its own Q2 results on May 7 with expectations of $0.35 in earnings and revenues exceeding $554 million.
๐ Cencora missed earnings and revenue estimates, reporting Q2 EPS of $4.75.
๐ฐ Stock dropped 9.4% this year while the S&P 500 gained 6%.
๐ฎ Future price movement depends on management commentary during the earnings call.
๐ Cencora reported Q2 earnings of $4.75 per share, missing the consensus estimate of $4.80.
๐ฐ Year-over-year adjusted earnings grew from $4.42 to $4.75 per share for the latest quarter.
๐ Revenue reached $78.36 billion, falling short of the consensus estimate by nearly 3%.
๐ Annualized revenue grew to $17.58 billion in the current fiscal year compared to last year's $17.58 billion? Wait, checking text: "current fiscal year" revenues are projected at $346.07 billion in the outlook section, but let's stick to the reported figures vs estimates.
๐ค The stock has lost about 9.4% since the start of the year while the S&P 500 gained 6%.
๐ฎ Management commentary on the earnings call will be crucial for determining near-term price movement.
๐ Current consensus EPS and revenue estimates are $4.35 and $87.24 billion respectively for the coming quarter.
๐ The Zacks Rank for Cencora is currently a #3 (Hold) based on mixed earnings estimate revisions prior to the report.
๐ฅ Cencora operates within the Medical Services industry, which ranks in the top 39% of all Zacks industries.
โ๏ธ Historical data shows that top-ranked industries outperform bottom ones by more than a factor of two.
โณ Concentra Group (CON), a peer company, is yet to report its quarter ended March 2026 results.
๐ Concentra Group is expected to release its earnings on May 7, targeting $0.35 per share in EPS.
๐ฐ Concentra Group's projected revenue is $554.26 million, representing a 10.7% increase year-over-year.
๐ Investors can track future stock performance by monitoring trends in earnings estimate revisions.
Bullish Signals
Delivered $4.75 EPS in Q1 2026 vs last year's $4.42.
Beat revenue consensus twice over the past four quarters.
Grew revenues to $78.36 billion from $75.45 billion.
Industry ranks top 39% with strong historical outperformance.
Peer Concentra (CON) projects 10.7% revenue growth and $0.35 EPS.
Cencora delivered earnings of $4.75 per share for the quarter ended March 2026, which compares favorably to last year's $4.42 per share despite missing consensus by a small margin.
The company has topped consensus revenue estimates two times over the last four quarters, demonstrating an ability to beat expectations periodically.
Cencora's revenues grew to $78.36 billion from the year-ago level of $75.45 billion, showing consistent top-line growth.
The Zacks Medical Services industry is currently ranked in the top 39% of all Zacks-ranked industries, placing Cencora in a strong relative position that historically outperforms the bottom half by a factor of more than 2 to 1.
Competition remains robust within the sector as peer Concentra Group Holdings Parent (CON) expects significant growth with projected earnings of $0.35 per share and revenues rising 10.7% in its upcoming March quarter report.
Investors can access Zacks Investment Research's comprehensive analysis, including a list of today's top-ranked stocks to identify further upside potential.
Risk Factors
Cencora reported Q2 earnings of $4.75 per share, missing the Zacks Consensus Estimate of $4.8 per share by -1.04%.
The company posted revenues of $78.36 billion for the quarter ended March 2026, falling short of the consensus estimate by 2.98%.
Cencora shares have underperformed significantly this year, losing approximately 9.4% compared to the S&P 500's gain of 6%.
The stock currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform merely in line with the market rather than outperforming.
Investors face uncertainty regarding future earnings estimate revisions, which have historically correlated strongly with near-term stock price movements.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)